M
The startup utilizes microbial biomarkers, liquid biopsy technology, genomic sequencing, and bioinformatics to detect cancer-associated microbes in blood samples. This approach enables early-stage cancer detection, improving patient outcomes by facilitating timely medical intervention.
Updated 3 months ago
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup utilizes microbial biomarkers, liquid biopsy technology, genomic sequencing, and bioinformatics to detect cancer-associated microbes in blood samples. This approach enables early-stage cancer detection, improving patient outcomes by facilitating timely medical intervention.